Drug Profile
Human rhodopsin - Kubota Vision
Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator University of Manchester
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinitis pigmentosa
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in USA (Intravitreous)
- 01 Nov 2021 Human rhodopsin is still in preclinical trials for Retinitis pigmentosa in USA (Kubota Vision pipeline, November 2021)
- 01 Nov 2021 Kubota Vision plans to file IND application for Retinitis pigmentosa